VCNX - Vaccinex, Inc P/S Multiple

Brandmark of Vaccinex Inc (VCNX)

Vaccinex, Inc. (VCNX) is a recognized expert in developing antibodies against oncology and brain degeneration. Historical P/S dynamics demonstrate volatility driven by the unique SEMA4D platform for combating Alzheimer's disease, yet constrained by the risk of cash depletion. The value is currently held at 9.30, allowing for a real-time assessment of the business's market value relative to its revenue volumes.

VCNX (Vaccinex, Inc) Price-to-Revenue Ratio history from 07/04/2022 to 12/21/2024

Vaccinex, Inc (VCNX) - metric breakdowns and financial figures

- market price and analyst price targets:
Stock Quotes vaccinex.com|VCNX - Consensus Target
- market capitalization statistics:
Market Capitalization Vaccinex, Inc|VCNX - Total Company Value
- balance sheet equity data:
Equity per Share Vaccinex|VCNX - Company Book Value|Market-to-Book Ratio vaccinex.com|VCNX - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Ratio Vaccinex, Inc.|VCNX - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Vaccinex Inc|VCNX - Company Aggregate Debts|Debt to Net Assets Ratio Vaccinex, Inc|VCNX - Company Long-Term Debts|Short-Term Debt Vaccinex|Intermediate Coverage Ratio vaccinex.com
- net income and valuation multiples indicators:
VCNX - Net Profit|Projected Future Earnings Vaccinex, Inc.|VCNX - Price to Earnings Ratio|Price to Expected Earnings Ratio Vaccinex Inc.|VCNX - Price/Earnings to Growth Multiple|Company Value to EBITDA Vaccinex, Inc|VCNX - Operating profit before deduction of amortization|Earnings per share for the last twelve months Vaccinex|VCNX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth vaccinex.com|VCNX - Earnings growth in current year|Expected earnings per share growth for next year Vaccinex, Inc.
- total revenue and sales volume data:
VCNX - Revenue and Sales Volume|Company Future Sales Volume vaccinex.com|VCNX - P/S Multiple|Market Cap to Expected Sales Ratio Vaccinex, Inc
General company analysis:vaccinex.com, VCNX
Manufactured product of Vaccinex Inc.

For the biotech leader Vaccinex, Inc. (VCNX), which is developing the innovative SEMA4D antibody platform, the company's P/S ratio serves as an indicator of market expectations regarding the commercialization of its R&D potential. This ratio is calculated as the relationship between market capitalization and annual sales volume, allowing investors to determine the cost per unit of revenue and assess the premium paid for the issuer's future technological success within the neurodegenerative disease sector.

Competing companies

Market Cap to Revenue immunitybio.com IBRX|Immunocore - Market Cap to Revenue|P/S Multiple Janux Therapeutics Inc JANX|RCUS - Price-to-Revenue Ratio|ZYME (Zymeworks Biopharmaceuticals) - Market Cap to Revenue Ratio|Tango Therapeutics (TNGX) - Price-to-Revenue Ratio|Price to Sales iovance.com (IOVA)|Market Cap to Revenue IMTX|XNCR - Price-to-Revenue Multiple|Market Cap to Revenue CMPX (Compass Bio)|Market Cap to Sales Volume REPL|P/S Multiple LYEL (Lyell Immunopharma)|Market Capitalization-to-Revenue Ratio IPHA|Pyxis - P/S Multiple|Price to Sales Compugen Ltd.|IO Biotech Corp (IOBT) - Price-to-Revenue Ratio|Sutro Biopharma, Inc - Market Capitalization-to-Revenue Ratio|INKT (MiNK Therapeutics, Inc.) - P/S Multiple|P/S Multiple Werewolf|Price-to-Revenue Ratio Immix Biopharma, Inc. (IMMX)|ALXO: Price-to-Sales Ratio|Cue Biopharma, Inc. - Market Cap to Revenue|PDS Biotech (PDSB) - Price to Sales|SONN: Market Cap to Revenue|MAIA: Price-to-Revenue Ratio|LIMN: P/S Multiple|LAVA Therapeutics (LVTX) - P/S Multiple|NXTC (NextCure Corp) - P/S Multiple|Market Cap to Revenue Leap Tx (LPTX)|P/S Multiple INTS|Market Cap to Revenue senseibio.com SNSE|P/S Multiple TOVX (Theriva Biologics)|Price-to-Revenue Coefficient Gritstone bio Inc. (GRTS)|KA - Price-to-Revenue Ratio|NEXI (NexImmune Corporation) - Market Cap to Revenue Ratio|TSBX: P/S Multiple|Price to Sales harpoontx.com (HARP)